News & Events

• Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
  Published on 2025-03-13
• Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025
  Published on 2025-03-04
• Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
  Published on 2025-03-03
• Genetic Analysis AS publishes year-end report 2024
  Published on 2025-02-26
• Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
  Published on 2025-01-16
• Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
  Published on 2025-01-09
• GENETIC ANALYSIS AND FERRING PHARMACEUTICALS ANNOUNCE A COLLABORATION TO DEVELOP A NEW MICROBIOME RAPID DIAGNOSTIC TEST
  Published on 2024-12-20
• Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference
  Published on 2024-12-16
• FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
  Published on 2024-12-09
• Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
  Published on 2024-11-22
• Publication of Q3 Interim Report January – September 2024
  Published on 2024-11-15
• Genetic Analysis AS: Interim report January – September 2024
  Published on 2024-11-15
• Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
  Published on 2024-11-13
• Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
  Published on 2024-11-06
• Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes
  Published on 2024-10-16